Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 10/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 10/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CFB | P00751 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 3/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL16699530 | 0.94 | ADRA2A (0.42) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL4638692 | 0.91 | ADRA2A (0.44) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Acetic Acid SCHEMBL4639185 | 0.85 | ADRA2A (0.40) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL8926989 | 0.84 | ADRA2A (0.52) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL6581550 | 0.82 | ADRA2A (0.50) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL6950536 | 0.82 | ADRA2A (0.50) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL6579371 | 0.81 | ADRA2A (0.44) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL6967227 | 0.81 | ADRA2A (0.49) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL7210059 | 0.81 | ADRA2A (0.46) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL6579461 | 0.80 | ADRA2A (0.43) | ADRA2AADRA1AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| EP-1037887-B1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | PROCTER & GAMBLE (US) | 2004-07-14 | — | — | EP | claimed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | claimed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | claimed |
| US-12612570-B2 | Unleaded avgas composition | GENERAL AVIATION MODIFICATIONS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12534383-B2 | High temperature chemical process for the preparation of cesium tungstate | CARDARELLI FRANCOIS (CA) | 2026-01-27 | — | — | US | disclosed |
| US-12305135-B2 | High octane unleaded aviation gasoline | GENERAL AVIATION MODIFICATIONS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250136883-A1 | UNLEADED AVGAS COMPOSITION | GENERAL AVIATION MODIFICATIONS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-13 | — | — | US | disclosed |
| US-20250017104-A1 | DISPLAY APPARATUS, DISPLAY MODULE, AND ELECTRONIC DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-01-09 | — | — | US | disclosed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6066740-A | Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives | THE PROCTER & GAMBLE COMPANY (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0944603-A1 | PROCESS FOR MAKING 2-AMINO-2-IMIDAZOLINE, GUANIDINE, AND 2-AMINO-3,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998023595-A1 | PROCESS FOR MAKING 2-AMINO-2-IMIDAZOLINE, GUANIDINE, AND 2-AMINO-3,4,5,6-TETRAHYDROPYRIMIDINE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA1A 7/4885ADRA2B 4/4885 |
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | ADORA2A, HCRTR1, ADORA1 | ADRA2A 215/4885ADRA1A 234/4885ADRA2B 326/4885 |
| US-12534383-B2 | High temperature chemical process for the preparation of cesium tungstate | SOD1, SOD3, CA3 | ADRA2A 4749/4885ADRA1A 4799/4885ADRA2B 4712/4885 |
| US-12612570-B2 | Unleaded avgas composition | POLG, ALPG, AP1G1 | ADRA2A 816/4885ADRA1A 568/4885ADRA2B 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.